I den samlede patientpopulation i studie MF4411, sås ingen reduktion af non- vertebrale frakturer, selvom dagligt indtag af ibandronat tilsyneladende havde effekt i en høj- risiko- undergruppe (lårbenshalsen BMD T- score < - 3, 0), hvor en risikoreduktion på 69% blev observeret.
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronate appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score < -3.0), where a non-vertebral fracture risk reduction of 69% was observed.